173 related articles for article (PubMed ID: 38536527)
1. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.
Kang NN; Zheng H; Hu JX; Cui K; Si PP; Ge W
Kaohsiung J Med Sci; 2024 Mar; 40(3):291-295. PubMed ID: 38088519
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.
Qiao Y; Zhao C; Li X; Zhao J; Huang Q; Ding Z; Zhang Y; Jiao J; Zhang G; Zhao S
Front Immunol; 2022; 13():953229. PubMed ID: 35911723
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
Zhou RQ; Luo J; Li LJ; Du M; Wu QC
BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
10. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Lv H; Huang C; Li J; Zhang F; Gai C; Liu Z; Xu S; Wang M; Li Z; Tian Z
Front Immunol; 2022; 13():1100750. PubMed ID: 36741358
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
[TBL] [Abstract][Full Text] [Related]
14. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Loc NVV; Vuong NL; Trung LV; Trung TT
J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785
[TBL] [Abstract][Full Text] [Related]
15. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
16. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
18. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S
Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630
[TBL] [Abstract][Full Text] [Related]
19. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
20. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]